If the last few years has done anything, it’s made people more health conscious.
An area of medicine that is gaining in popularity is regenerative medicine. Rather than pharmaceutical fixes, it uses all-natural biological protocols to stimulate the body to repair or heal damaged tissue and joints.
It works as an alternative to surgery, pain killers and non-steroidal anti-inflammatory drugs, which mask rather than repair problems. This area of medicine is considered to be the next frontier in the treatment of conditions such as musculoskeletal injury, arthritis, chronic pain and joint problems.
The prevalence of such problems will likely increase, due to New Zealand’s aging population. Stats NZ’s long-term population projections predict increasing numbers and proportions of older people in the population.
The population aged 65+ (0.79 million in 2020) has a 90% probability of increasing to between 1.34 and 1.46 million in 2048, an increase of up to 25%.
Regenerative non-surgical medicine techniques like stem cell therapy and infusions treatments are also likely to increase as a result, as an alternative to surgical interventions.
American regenerative franchise brand QC Kinetix®, which launched in early 2021, has just opened its 140th clinic in the US. Its business model is described as ‘concierge medicine’ – no haggling with insurance companies. Patients pay upfront and get a very high level of care and service with state-of-the-art treatments.
Treatments are customised to the patient. And while surgery can be traumatic with long recovery times, and pain killers can be addictive, regenerative medicine has none of those pitfalls. It’s increasingly the direction medicine is going.
In the case of stem cells, these have high power of regeneration and trigger production of other cells in the body. This has increased demand for stem cell therapy in the treatment of degenerative diseases. QC Kinetix® uses the stem cells of each patient for their treatments.
In fact, the Centre for Commercialisation of Regenerative Medicine has reported there are about 1900 active clinical trials on stem cells currently taking place, and 574 active industry-sponsored cell therapy clinical studies. So, it’s likely stem cell therapy will contribute to the growth of the regenerative medicine market.
The sector as a whole was valued at US$6 billion in 2020, and is predicted to hit US$13 billion by the end of 2028.
The good news for Kiwi investors is that QC Kinetix ®is now looking for licensees in New Zealand. Franchisees can own their own clinic for a modest investment, but with plenty of potential for good returns, and backed by a team of international professionals.
The Franchise Coach’s Stewart Germann, an award-winning franchise expert, says this is an opportunity to get in early to this nascent industry in New Zealand.
“Investment by the private and government sectors in this area globally is boosting market growth. As the science continues to show benefits in regenerative treatment, this arm of medicine is likely to become more mainstream. It’s still relatively new in New Zealand with a handful of private clinics, but probably not for long.”
To find out more about The QC Kinetix® franchise opportunity, contact The Franchise Coach Stewart Germann today at 021 276 9898 or at firstname.lastname@example.org.